Fig. 4.

Forest plots showing differences for active treatments versus placebo in outcomes at 24 weeks. a CFB mean trough FEV₁, b CFB mean SGRQ total score, c mean TDI focal score, d CFB mean rescue medication use (puffs/day). Results are reported as the mean with the 95% credible interval (Crl) in parenthesis, followed by the percentage probability of improved outcome versus placebo. Black dotted lines represent MCID values. ^aCombined dose taken twice daily, ^bFOR dose taken twice daily, ^cSAL dose taken twice daily. All other doses are taken once daily. ACL aclidinium, CFB change from baseline, CrI credible interval, FEV ₁ forced expiratory volume in 1 second, FOR formoterol, GLY glycopyrronium, IND indacaterol, MCID minimal clinically important difference, OLO olodaterol, SAL salmeterol, SGRQ St George’s Respiratory Questionnaire, TDI transition dyspnea index, TIO tiotropium, UMEC umeclidinium, VI vilanterol